Press "Enter" to skip to content

Sino Biopharmaceutical Limited (1177 HK) has obtained approval for drug registration

Sino Biopharmaceutical Limited (1177 HK) announces that the anti-tumor drug “Abiraterone Acetate Tablet” developed by Chia Tai – Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of the Company, has obtained approval for drug registration granted by the National Medical Products Administration of the People’s Republic of China. The Abiraterone Acetate Tablet developed by the Group was the second of its type to obtain approval for drug registration in China.

Sino Biopharm (1177) expects the launch of the Abiraterone Acetate Tablet developed by the Group will fill the gaps in the existing treatment of metastatic castration-resistant prostate cancer in China and reduce the burden of medication on patients to truly benefit patients.

Related | 相關文章  Taihe Rural Micro-finance (1915 HK) transfer of Listing

Comments are closed.